Emory University

Children's Healthcare of Atlanta, Inc.

Yuhong Du

Thota Ganesh

Jianxiong Jiang

Haian Fu

Ray J Dingledine

Pahk Thepchatri

Yi Quan

Keqiang Ye

Huw M Davies

Zhi Ren

Andras Rab

Xun Yang

Candela Manfredi

Eric Sorscher

Jeong Hong

This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managing a CFTR related disease or condition or respiratory distress comprising administering an effective amount of a CFTR modulator disclosed herein to a subject in need thereof.

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions, and uses thereof

This disclosure relates to asparagine endopeptidase inhibitors for managing cancer and compositions related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are substituted 3,7-dihydropurine-2,6-dione derivatives useful for treating or preventing metastasis, tumor growth, and/or cancer. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising an asparagine endopeptidase inhibitor and a pharmaceutically acceptable excipient. In certain embodiments, the disclosure relates to methods of treating a cancer comprising administering an effective amount of pharmaceutical composition a asparagine endopeptidase inhibitor disclosed herein to a subject in need thereof.

Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto

The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto

The present invention is directed to compounds of Formula IC: 

Growing community of inventors

Atlanta, GA, United States of America

Yuhong Du